US pharma major Eli Lilly (NYSE: LLY) saw its shares close down 3.19% at $108.36 yesterday, despite releasing positive clinical trial results with its interleukin (IL)-17 inhibitor compared to the world’s best selling prescription drug Humira (adalimumab).
Lilly announced that its Taltz (ixekizumab) met the primary and all major secondary endpoints in the Phase IIIb/IV SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive.
The SPIRIT-H2H trial is the first completed large head-to-head (H2H) superiority study in active PsA. This open-label, randomized, controlled trial is the first and only H2H study that utilizes on-label dosing for both Taltz and Humira and includes concomitant conventional DMARDs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze